Scarica l'app Stockscreener
1.87
7.91%
0.13
Precedente Chiudi:
$1.74
Aprire:
$1.78
Volume 24 ore:
633.91K
Relative Volume:
0.94
Capitalizzazione di mercato:
$64.23M
Reddito:
-
Utile/perdita netta:
$-28.85M
Rapporto P/E:
-1.3337
EPS:
-1.4021
Flusso di cassa netto:
$-25.62M
1 W Prestazione:
-2.21%
1M Prestazione:
-7.51%
6M Prestazione:
-12.67%
1 anno Prestazione:
+19.59%
Intervallo 1D:
$1.75
$1.935
Intervallo di 1 settimana:
$1.73
$1.97
Portata 52W:
$1.355
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.86 | 60.09M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
430.57 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.42 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
794.55 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.31 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.97 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile
Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - ChartMill
Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart
Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks
Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView
Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn
Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan
Form 424B5 Annovis Bio, Inc. - StreetInsider
Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com
Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS
Annovis Bio prices $10M stock offering at $1.90 per share By Investing.com - Investing.com South Africa
Annovis announces $10 million underwritten offering of common stock and accompanying warrants - marketscreener.com
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - The Manila Times
Annovis Secures U.S. Patent for Buntanetap Neurological Use - MyChesCo
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - WFXG
Annovis Bio Highlights Buntanetap Development in Published Article - MyChesCo
Will Annovis Bio Inc benefit from government policyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Options Flow: Can Annovis Bio Inc deliver consistent dividendsChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Growth Value: Whats the analyst consensus on Annovis Bio IncMarket Movers & Verified Chart Pattern Signals - baoquankhu1.vn
Annovis Strengthens Patent Portfolio With Buntanetap, Stock Up - RTTNews
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ANVS.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat
Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView — Track All Markets
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents - Quiver Quantitative
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):